跳至主要内容
临床试验/DRKS00030597
DRKS00030597招募中不适用

Metabolic health in neurodegenerative diseases - implications of metabolic characteristics and gut microbiome - NeuroBiom

Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn0 个研究点目标入组 100 人开始时间: 2023年2月7日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
50 Years 至 75 Years(—)
性别
All

入选标准

  • BMI 18,5-39,9 kg/m²
  • Non-smoker (for at least 3 months)
  • written declaration of consent for participation in the study.
  • Diagnosis Parkinson disease or Alzheimer disease
  • PD based on clinical diagnosis according to Brain Bank criteria(Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. JNNP 1992;55:181-184.)
  • Hoehn & Yahr stadium 1-3
  • Clinical and biomarker-based diagnosis with Alzheimer's pathology based on typical CSF findings
  • Mixed dementia with a vascular component (up to Fazekas II) is permitted.

排除标准

  • Taking medications that affect glucose metabolism
  • chronic hepatic diseases, gastrointestinal diseases, chronic inflammatory diseases or other severe diseases
  • antibiotic therapy 3 weeks before the start of the study
  • Planned lifestyle changes
  • regular intake of supplements
  • drug abuse
  • participation in another clinical trial simultaneously/in the last 30 days
  • Atypical PD syndromes
  • severe motor fluctuations
  • Dementia of unclear origin
  • Heavy vascular part (Fazekas III)

研究者

发起方
Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn

相似试验

Metabolic health in neurodegenerative diseases -... | 临床试验